Vascular risk screening: Possible or too much, too soon?

International Journal of Clinical Practice

Volumn 63, Issue 7, 2009, Pages 989-996

  Wierzbicki, A S ^a   Reynolds, T M ^b  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b QUEEN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; VARENICLINE;

ALGORITHM; ANTIHYPERTENSIVE THERAPY; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL FEATURE; CLINICAL PRACTICE; DIABETES MELLITUS; DRUG EFFICACY; DYSLIPIDEMIA; ETHNICITY; FAMILY HISTORY; GROUPS BY AGE; HIGH RISK POPULATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; ISCHEMIC HEART DISEASE; LIFESTYLE; METABOLIC SYNDROME X; OBESITY; PATIENT IDENTIFICATION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; REVIEW; SCREENING; SEX DIFFERENCE; TOBACCO DEPENDENCE; CARDIOVASCULAR DISEASES; EVIDENCE BASED MEDICINE; MASS SCREENING; PROCEDURES; RISK ASSESSMENT; RISK FACTOR;

ALGORITHMS; CARDIOVASCULAR DISEASES; EVIDENCE-BASED MEDICINE; HUMANS; MASS SCREENING; RISK ASSESSMENT; RISK FACTORS;

EID: 67650756826     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2009.02111.x     Document Type: Review

References (72)

1. Yusuf S, Hawken S, Ounpuu S et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004 364 : 937 52.
2. Stamler J. The marked decline in coronary heart disease mortality rates in the United States, 1968-1981; summary of findings and possible explanations. Cardiology 1985 72 : 11 22. (Pubitemid 15163595)
3. Sytkowski PA, D'Agostino RB, Belanger A et al. Sex and time trends in cardiovascular disease incidence and mortality: the Framingham Heart Study, 1950-1989. Am J Epidemiol 1996 143 : 338 50.
4. O'Hara T, Bennett K, O'Flaherty M et al. Pace of change in coronary heart disease mortality in Finland, Ireland and the United Kingdom from 1985 to 2006. Eur J Public Health 2008 18 : 581 5.
5. Department of Health. National Service Framework for Coronary Heart Disease. London : Department of Health, 2000.
6. DH Coronary Heart Disease Policy Team. Building for the future: The Coronary Heart Disease National Service Framework. London, UK : Department of Health, 2008. Report No.: 285773.
7. Vascular Programme. Putting Prevention First - Vascular Checks: Risk Assessment and Management. London, UK : Department of Health, 2008. Report No.: 287093.
8. Multiple Risk Factor Intervention Trial Research Group. Multiple risk factor intervention trial. Risk factor changes and mortality results. JAMA 1982 248 : 1465 77.
9. Imperial Cancer Research Fund OXCHECK Study Group. Effectiveness of health checks conducted by nurses in primary care: final results of the OXCHECK study. BMJ 1995 310 : 1099 104.
10. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2007 : CD006103.
11. Eisenberg MJ, Filion KB, Yavin D et al. Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. CMAJ 2008 179 : 135 44.
12. Antiplatelet Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002 324 : 71 86.
13. Duprez DA, Florea ND, Jones K et al. Beneficial effects of valsartan in asymptomatic individuals with vascular or cardiac abnormalities: the DETECTIV Pilot Study. J Am Coll Cardiol 2007 50 : 835 9.
14. Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995 333 : 1301 7.
15. Ridker PM, Danielson E, Fonseca FA et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008 359 : 2195 207.
16. Nakamura H, Arakawa K, Itakura H et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 2006 368 : 1155 63.
17. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003 326 : 1419.
18. Sheridan S, Pignone M, Mulrow C. Framingham-based tools to calculate the global risk of coronary heart disease: a systematic review of tools for clinicians. J Gen Intern Med 2003 18 : 1039 52.
19. Anderson KM, Odell PM, Wilson PW et al. Cardiovascular disease risk profiles. Am Heart J 1991 121 (1 Pt 2 293 8.
20. Assmann G, Schulte H, Cullen P et al. Assessing risk of myocardial infarction and stroke: new data from the Prospective Cardiovascular Munster (PROCAM) study. Eur J Clin Invest 2007 37 : 925 32.
21. Conroy RM, Pyorala K, Fitzgerald AP et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003 24 : 987 1003. (Pubitemid 36712275)
22. Hippisley-Cox J, Coupland C, Vinogradova Y et al. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ 2007 335 : 136.
23. Hippisley-Cox J, Coupland C, Vinogradova Y et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ 2008 336 : 1475 82.
24. Mainous AG III., Koopman RJ, Diaz VA et al. A coronary heart disease risk score based on patient-reported information. Am J Cardiol 2007 99 : 1236 41.
25. Brindle P, Beswick A, Fahey T et al. Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review. Heart 2006 92 : 1752 9.
26. Lloyd-Jones DM, Leip EP, Larson MG et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation 2006 113 : 791 8.
27. Stampfer MJ, Hu FB, Manson JE et al. Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med 2000 343 : 16 22. (Pubitemid 30447987)
28. Stamler J, Neaton JD. The Multiple Risk Factor Intervention Trial (MRFIT) - importance then and now. JAMA 2008 300 : 1343 5.
29. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society et al. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998 80 (Suppl. 2 S1 29.
30. British Cardiac Society, British Hypertension Society, Diabetes UK et al. JBS 2: the Joint British Societies' guidelines for prevention of cardiovascular disease in clinical practice. Heart 2005 91 (Suppl. V v1 52.
31. Woodward M, Brindle P, Tunstall-Pedoe H. Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC). Heart 2007 93 : 172 6.
32. Brindle P, May M, Gill P et al. Primary prevention of cardiovascular disease: a web-based risk score for seven British black and minority ethnic groups. Heart 2006 92 : 1595 602.
33. Stevens RJ, Coleman RL, Holman RR. Framingham risk equations underestimate coronary heart disease risk in diabetes. Diabet Med 2005 22 : 228. (Pubitemid 40204336)
34. Kannel WB, Cupples LA, Ramaswami R et al. Regional obesity and risk of cardiovascular disease; the Framingham Study. J Clin Epidemiol 1991 44 : 183 90.
35. Reynolds TM, Wierzbicki AS, Twomey PJ. Epidemiological studies are meaningless without proof of long-term data stability. Am J Med 2008 121 : e7 10.
36. Durrington PN, Prais H, Bhatnagar D et al. Indications for cholesterol-lowering medication: comparison of risk-assessment methods. Lancet 1999 353 : 278 81.
37. Omboni S, Costantini C, Pini C et al. PA.NET International Quality Certification Protocol for blood pressure monitors. Blood Press Monit 2008 13 : 285 9.
38. Linnet K. Necessary sample size for method comparison studies based on regression analysis. Clin Chem 1999 45 (6 Pt 1 882 94.
39. Reynolds TM, Twomey P, Wierzbicki AS. Accuracy of cardiovascular risk estimation for primary prevention in patients without diabetes. J Cardiovasc Risk 2002 9 : 183 90.
40. Reynolds TM, Twomey PJ, Wierzbicki AS. Concordance evaluation of coronary risk scores: implications for cardiovascular risk screening. Curr Med Res Opin 2004 20 : 811 8.
41. Neil HA, Perera R, Armitage JM et al. Estimated 10-year cardiovascular risk in a British population: results of a national screening project. Int J Clin Pract 2008 62 : 1322 31.
42. Marshall T, Rouse A. Resource implications and health benefits of primary prevention strategies for cardiovascular disease in people aged 30 to 74: mathematical modelling study. BMJ 2002 325 : 197.
43. Lloyd-Jones DM, Nam BH, D'Agostino RB Sr. et al. Parental cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults: a prospective study of parents and offspring. JAMA 2004 291 : 2204 11.
44. Schaefer EJ, Genest JJ Jr., Ordovas JM et al. Familial lipoprotein disorders and premature coronary artery disease. Atherosclerosis 1994 108 (Suppl. S41 54.
45. Sattar N, Gaw A, Scherbakova O et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003 108 : 414 9.
46. Parikh NI, Pencina MJ, Wang TJ et al. A risk score for predicting near-term incidence of hypertension: the Framingham Heart Study. Ann Intern Med 2008 148 : 102 10.
47. McLaughlin T, Abbasi F, Lamendola C et al. Heterogeneity in the prevalence of risk factors for cardiovascular disease and type 2 diabetes mellitus in obese individuals: effect of differences in insulin sensitivity. Arch Intern Med 2007 167 : 642 8.
48. Hanley AJ, Williams K, Gonzalez C et al. Prediction of type 2 diabetes using simple measures of insulin resistance: combined results from the San Antonio Heart Study, the Mexico City Diabetes Study, and the Insulin Resistance Atherosclerosis Study. Diabetes 2003 52 : 463 9.
49. Balkau B, Hu G, Qiao Q et al. Prediction of the risk of cardiovascular mortality using a score that includes glucose as a risk factor. The DECODE Study. Diabetologia 2004 47 : 2118 28.
50. National Institute for Health and Clinical Excellence. Lipid Modification. London, UK : National Institute for Health and Clinical Excellence, 2008. Report No.: CG67.
51. Simons LA. Interrelations of lipids and lipoproteins with coronary artery disease mortality in 19 countries. Am J Cardiol 1986 57 : 5G 10G. (Pubitemid 16011552)
52. Wilson PW, D'Agostino RB, Levy D et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998 97 : 1837 47.
53. Gaziano TA, Young CR, Fitzmaurice G et al. Laboratory-based versus non-laboratory-based method for assessment of cardiovascular disease risk: the NHANES I Follow-up Study cohort. Lancet 2008 371 : 923 31.
54. Almdal T, Scharling H, Jensen JS et al. Higher prevalence of risk factors for type 2 diabetes mellitus and subsequent higher incidence in men. Eur J Intern Med 2008 19 : 40 5.
55. Perticone F, Maio R, Ruberto C et al. Kidney function and risk factors for left ventricular hypertrophy in untreated uncomplicated essential hypertension. Am J Kidney Dis 2008 52 : 74 84. (Pubitemid 351853261)
56. Bhopal R, Hayes L, White M et al. Ethnic and socio-economic inequalities in coronary heart disease, diabetes and risk factors in Europeans and South Asians. J Public Health Med 2002 24 : 95 105. (Pubitemid 34712385)
57. Wierzbicki AS. Surrogate markers, atherosclerosis and cardiovascular disease prevention. Int J Clin Pract 2008 62 : 981 7.
58. McCluskey S, Baker D, Percy D et al. Reductions in cardiovascular risk in association with population screening: a 10-year longitudinal study. J Public Health (Oxf) 2007 29 : 379 87.
59. Marshall T, Westerby P, Chen J et al. The Sandwell Project: a controlled evaluation of a programme of targeted screening for prevention of cardiovascular disease in primary care. BMC Public Health 2008 8 : 73.
60. Richardson G, van Woerden HC, Morgan L et al. Healthy hearts - a community-based primary prevention programme to reduce coronary heart disease. BMC Cardiovasc Disord 2008 8 : 18.
61. Lloyd CE, Johnson MR, Mughal S et al. Securing recruitment and obtaining informed consent in minority ethnic groups in the UK. BMC Health Serv Res 2008 8 : 68.
62. Kim LG, Thompson SG, Marteau TM et al. Screening for abdominal aortic aneurysms: the effects of age and social deprivation on screening uptake, prevalence and attendance at follow-up in the MASS trial. J Med Screen 2004 11 : 50 3.
63. Bouchard MH, Dragomir A, Blais L et al. Impact of adherence to statins on coronary artery disease in primary prevention. Br J Clin Pharmacol 2007 63 : 698 708. (Pubitemid 46753568)
64. Penning-van Beest FJ, Termorshuizen F, Goettsch WG et al. Adherence to evidence-based statin guidelines reduces the risk of hospitalizations for acute myocardial infarction by 40%: a cohort study. Eur Heart J 2007 28 : 154 9.
65. The South-East London Screening Study Group. A controlled trial of multiphasic screening in middle-age: results of the South-East London Screening Study. Int J Epidemiol 1977 6 : 357 63.
66. Versmissen J, Oosterveer DM, Yazdanpanah M et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ 2008 337 : a2423.
67. Graham I, Atar D, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007 14 (Suppl 2 S1 113.
68. Ridker PM, Paynter NP, Rifai N et al. C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men. Circulation 2008 118 : 2243 51, 4p.
69. Ridker PM, Buring JE, Rifai N et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. JAMA 2007 297 : 611 9.
70. Stevens RJ, Kothari V, Adler AI et al. The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci (Lond) 2001 101 : 671 9.
71. Grundy SM, Pasternak R, Greenland P et al. AHA/ACC scientific statement: Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. J Am Coll Cardiol 1999 34 : 1348 59.
72. D'Agostino RB Sr., Vasan RS, Pencina MJ et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008 117 : 743 53.